TenderlineUK
Procurement Intelligence
Official OCDS
Find a Tender
complete
Official procurement procedure

Community Hydroxychloroquine and Chloroquine Monitoring Service - Bradford District and Craven Health and Care Partnership

Health services
Yorkshire & Humber (UKE)
Published value
Not published
Submission deadline Not published
Lots published1
Procurement Executive Summary
AI & Search Synopsis
Generated from official OCDS record
Tenderline Synopsis: NHS West Yorkshire Integrated Care Board: "Community Hydroxychloroquine and Chloroquine Monitoring Service - Bradford District and Craven Health and Care Partnership". Published status: complete. Published value: Value not published. 1 published lot. Submission deadline not published. See the official notice for participation instructions.
Contracting AuthorityNHS West Yorkshire Integrated Care BoardScope & CategoriesNot publishedSubmission Window
complete
No deadline published
Submission GatewayDirect notice routeLegal Basis & RegimeStandard procurementEstimated Value (exc. VAT)Not published
Bidder Intelligence · Authority Profile: NHS West Yorkshire Integrated Care Board
Market Analytics
View Authority Profile →
Derived from OCDS awards & bid statistics
Published history for NHS West Yorkshire Integrated Care Board. These figures describe retained records, not a forecast of bids or a measure of buyer bias.
Published-to-award variance
Not availableInsufficient comparable data
Requires at least 5 comparable procedures
Competition Density
31.3Bids / Report
9.5% of reports have one bid
Supplier ConcentrationNo estimate
Insufficient attributable awardsNo concentration estimate available
Payment Terms
Check noticePublished terms
Payment obligations depend on the applicable regime and contract. Consult the official documents.
Coverage: 76 active published awards; 63 bid reports (which may be per lot). Supplier values exclude multi-supplier awards, frameworks and DPS, and use GBP only. They are published award values, not payments. Published-to-award variance compares single-lot, single-award, single-supplier GBP procedures with explicitly non-framework/non-DPS status; increases remain in the average. Unpublished data stays unknown. Awarded suppliers are winners, not all bidders.
Procedure terms
Contracting AuthorityNHS West Yorkshire Integrated Care Board
Procedure methodNot published
Procurement categoryNot published
Statuscomplete
Framework / DPSNot published
CompetitionNot published
Above thresholdNot published
Legal basisNot published
Tender period startsNot published
Clarification deadlineNot published
Electronic submissionNot published
Submission languagesNot published
Published18 Jul 2023, 11:27 BST
Last source update18 Jul 2023, 11:27 BST
Recurring procurementNot published
ClassificationHealth services
Delivery area
Yorkshire & Humber (UKE)
OCIDocds-h6vhtk-03e2e5
What is being bought
A community service that provides routine monitoring of patients on Hydroxychloroquine (HCQ) as per the guidelines and recommendations of the Royal College of Ophthalmologists (Hydroxychloroquine Retinopathy Monitoring Guideline). however currently there is no service provision with BD&C HCP We have worked with a community provider, Shipley Ophthalmic Assessment Programme (SOAP), to create a monitoring provision to bridge this gap.
What changed
From the official release history
  1. Status changed to complete
    18 Jul 2023, 11:27 BST
  2. Official notice release published
    18 Jul 2023, 11:27 BST
  3. Buyer information updated
    18 Jul 2023, 11:27 BST
Lots and requirements (1)
Published by the contracting authority
  • Lot 1 · #1
    Individual lot title not published
    Status not published
    Published valueNot published
    A community service that provides routine monitoring of patients on Hydroxychloroquine (HCQ) as per the guidelines and recommendations of the Royal College of Ophthalmologists (Hydroxychloroquine Retinopathy Monitoring Guideline).
    Contract periodNot published
    EligibilityNot published
    Options / renewalNot published
Timeline
  1. Procedure published
    18 Jul 2023, 11:27 BST
  2. Award active
    Not published · Not published
  3. Contract active
    Signed 1 Mar 2023, 00:00 GMT · £75,615
Commercial outcome and competition
Awards
The Saltaire & Windhill Medical Partnership
Not published · Not published · active
Contracts
Contract
£75,615 · signed 1 Mar 2023, 00:00 GMT · active
Bid statisticsNo aggregate bid statistics published
Buyer and organisations in this procedure

NHS West Yorkshire Integrated Care Board

Contracting authority GB-FTS-57935
View buyer profile

  • NHS West Yorkshire Integrated Care Board
    buyer

    White Rose House, Wakefield, UK, WF1 1LT
    wyicb-kirk.procurement@nhs.net

  • Royal Court of Justice
    reviewBody

    Strand, Holborn, London, WC2A 2LL

  • The Saltaire & Windhill Medical Partnership
    supplier

    Cliffe Avenue, Shipley, UKE, BD17 6NX
Documents (0)
Official links; attachments are not copied
No data
No linked documents are published
Related procedures (0)
No data
No related procedures published
Planning and rationale
Planning budgetNot published
No-engagement rationaleNot published
Procedure rationaleRoutine monitoring of patients on Hydroxychloroquine (HCQ) is as per the guidelines and recommendations of the Royal College of Ophthalmologists (Hydroxychloroquine Retinopathy Monitoring Guideline), however currently there is no service provision with BD&C HCP. We have worked with a community provider, Shipley Ophthalmic Assessment Programme (SOAP), to create a monitoring provision to bridge this gap. HCQ is a medicine that is effective in treating various long-term inflammatory disorders of the joints and skin (usually prescribed in rheumatology/dermatology). In general, it is a safe and cost-effective medication, particularly when compared to newer anti-inflammatory medicines which can more significant adverse effects on the body. However, some patients taking hydroxychloroquine, or a similar medication called chloroquine, can suffer permanent loss of vision due to retinopathy. As a result of this, once prescribed the guidelines recommend that a baseline is taken of a patient’s eye health, and dependent upon some other factors, once a patient has been on this drug for 5 years they should begin routine annual monitoring to ensure that the retina is maintaining health. The monitoring of these patients has not been undertaken in BD&C HCP, with Hospital Eye Services (HES) unable to take on the burden of these patients from either a capacity (HES services were and are already overflowing), or capability (lack of further clinic space). WY colleagues are now raising the risk index on this matter as they now believe we have patients who have been unmonitored on HCQ for 7 years or slightly greater (2 years beyond the guidelines for routine monitoring), although they are working with Meds Mgt teams to accurately identify the specific cohort and the number of patients involved. Justification under which formal quotation/tendering process is to be waived: (g) where specialist expertise/service/works/goods are required, and these are available from only one source (specialised service).